During follow-up, Hs-CRP levels are good predictors of vascular events and recurrent stroke among patients of ischemic stroke. Pravastatin therapy may reduce vascular inflammation as assessed by Hs-CRP levels in study subjects with non-cardiogenic ischemic stroke. This evidence concerns the gene CRP and ischemic stroke.